Orchid Pharma Ltd (NSE: ORCHPHARMA, BSE: 524372) is a Chennai, Tamil Nadu-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹5,190 Cr, it ranks #824 by market cap among the 6,197 Indian listed companies on FinBizNet, and #24 of 86 in Medicinal Chemicals and Botanical Products. At ₹888.00 (as of 16 Nov 2026), the share price is 22.3% below its 52-week high of ₹1,143.50 and 85.0% above its 52-week low of ₹480.00. The share price is up 5.1% over one year and down 14.5% over three months.
| Current Price | ₹888.00 |
|---|---|
| Market Cap | ₹5,190 Cr |
| NSE Symbol | ORCHPHARMA |
| BSE Code | 524372 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 517.5 |
| Return on Equity | 0.70% |
| Return on Assets | 0.12% |
| 52-Week Range | ₹480.00 – ₹1,143.50 |
| 1-Year Price Change | +5.1% |
| 3-Month Price Change | -14.5% |
| Beta (1Y) | 0.81 |
| Headquarters | Chennai, Tamil Nadu |
| Website | www.orchidpharma.com |
| Revenue | ₹341 Cr |
|---|---|
| Net Profit | ₹29 Cr |
| Net Margin | 8.4% |
| EPS (Basic) | ₹4.77 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Orchid Pharma Ltd reported revenue of ₹341 Cr in Q2 FY27, up 76.3% from ₹194 Cr in Q2 FY26 and up 12.2% from ₹304 Cr in Q1 FY27. It posted a net profit of ₹29 Cr for the quarter, against a net loss of ₹6 Cr in Q2 FY26. Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹173 Cr (Q1 FY26) to ₹368 Cr (Q4 FY26). The company reported a net loss in 2 of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹341 Cr | ₹29 Cr | 8.4% |
| Q1 FY27 | ₹304 Cr | ₹3 Cr | 1.1% |
| Q4 FY26 | ₹368 Cr | ₹26 Cr | 7.0% |
| Q3 FY26 | ₹207 Cr | −₹13 Cr | −6.1% |
| Q2 FY26 | ₹194 Cr | −₹6 Cr | −3.0% |
| Q1 FY26 | ₹173 Cr | ₹15 Cr | 8.6% |
| Q4 FY25 | ₹237 Cr | ₹22 Cr | 9.4% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 74.45% of Orchid Pharma Ltd's shares as of Sept 2026, against 69.84% in Dec 2025 (+4.61 percentage points). Delivery averaged 47.5% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins; human and veterinary products; and antibiotics, including betalactam, macrolide, fluoroquinolone, and imidazole. The company also exports its products to approximately 40 countries internationally. The company was formerly known as Orchid Chemicals & Pharmaceuticals Limited and changed its name to Orchid Pharma Limited in October 2015. Orchid Pharma Limited was incorporated in 1992 and is headquartered in Chennai, India. Orchid Pharma Limited operates as a subsidiary of Dhanuka Laboratories Limited.
1. Pharmaceuticals-This segment engages in the research, manufacture, and marketing of active pharmaceutical ingredients and finished dosage forms. 2. Bulk-This segment manufactures active pharmaceuticals ingredients. 3. Formulation-This segment manufactures and sells finished dosage forms. 4. Corporate-0
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Orchid Pharma Ltd | ₹5,190 Cr | 517.5 | 0.70% | ₹341 Cr | +5.1% |
Listed by market capitalisation. Ratios are shown for context only.
Orchid Pharma Ltd is trading at ₹888.00, with a market capitalisation of ₹5,190 Cr.
Orchid Pharma Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Orchid Pharma Ltd has a P/E of 517.5 and a return on equity of 0.70%.
Orchid Pharma Ltd is listed on the NSE under the symbol ORCHPHARMA and on the BSE under the scrip code 524372.
Orchid Pharma Ltd's share price is up 5.1% over one year and down 14.5% over three months. Its 52-week range is ₹480.00 to ₹1,143.50.
In Q2 FY27, Orchid Pharma Ltd reported revenue of ₹341 Cr and net profit of ₹29 Cr, with basic EPS of ₹4.77 (consolidated, parsed from the company's exchange filing).
Orchid Pharma Ltd reported revenue of ₹341 Cr in Q2 FY27, up 76.3% from ₹194 Cr in Q2 FY26 and up 12.2% from ₹304 Cr in Q1 FY27.
Promoters held 74.45% of Orchid Pharma Ltd's shares as of Sept 2026, against 69.84% in Dec 2025 (+4.61 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.